Posted by Michael Wonder on 02 Jun 2020
Estimating the cost of delayed generic drug entry to Medicaid
1 June 2020 - Delays in market entry of generic drugs are common.
This study sought to identify the prevalence of delayed entry, the reasons for the delays, and the delays’ effects on Medicaid spending in a recent cohort of brand-name medications.
The investigators estimated excess Medicaid spending in 2010–16 in the delayed quarter-years after accounting for market average predictions of brand-name market share, ratios of generic to brand-name prices, and Medicaid rebates (60% for brand-name and 15% for generic drugs).
